Eric Jablon, MD
Ophthalmology · Charleston, SCNPI 1215042569
Payments from drug & device makers
Across 698 payments — averaging $1738.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$758K
- Ocular Therapeutix, Inc.$222K
- Janssen Research & Development, LLC$186K
- AbbVie$23K
- Genentech, Inc.$14K
- US Retina LLC$7K
- plus $4K from 22 others
What the payments were for
- Food & beverage$4,02335%
- Education$430%
- Gifts$4674%
- Ownership interest$2,88925%
- Other$4,15736%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 414 | $758,264 |
| Ocular Therapeutix, Inc. | 42 | $221,831 |
| Janssen Research & Development, LLC | 54 | $185,772 |
| AbbVie(2 entities) | 33 | $22,829 |
| Genentech, Inc. | 6 | $13,813 |
| US Retina LLC | 11 | $7,046 |
| Genentech USA, Inc. | 36 | $1,023 |
| Regeneron Healthcare Solutions, Inc. | 27 | $762 |
| Carl Zeiss Meditec, Inc. | 2 | $476 |
| Apellis Pharmaceuticals, Inc. | 10 | $236 |
| Eyepoint US, Inc. | 6 | $197 |
| Bausch & Lomb Americas Inc. | 11 | $189 |
| Novartis | 4 | $161 |
| Biogen | 7 | $139 |
| Dutch Ophthalmic, USA | 6 | $134 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $130 |
| Coherus Oncology, Inc. | 4 | $92 |
| Optos, Inc. | 2 | $88 |
| Alimera Sciences, Inc. | 5 | $80 |
| Sandoz | 2 | $55 |
| AstraZeneca | 1 | $43 |
| Alcon | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Harrow Eye, LLC | 1 | $17 |
| Amgen | 1 | $17 |
| Notal Vision, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VISUCAM Fundus Cameras$447
- VABYSMO$374
- EYLEA HD$128
- YUTIQ$113
How this compares
$1,213,518 in reported general payments places this provider in the 95th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lotemax SmLoteprednol Etabonate | 66 | $18,973 |
| Loteprednol Etabonate | 34 | $5,370 |
| Prednisolone Acetate | 109 | $3,718 |
| Difluprednate | 32 | $2,987 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $2,251 |
| Bromfenac Sodium | 12 | $2,006 |
| Ofloxacin | 89 | $828 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 38 | $757 |
| Latanoprost | 28 | $196 |
| Brimonidine Tartrate | 20 | $180 |
| Timolol Maleate | 16 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $130 | $24,343100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Charleston
- Daniel AlfaroCharleston$4.6M
- John KerrisonCharleston$975K
- Karolinne RochaCharleston$799K
- Mona CamacciCharleston$534K
- Marion WilsonCharleston$86K
- Drew DicksonCharleston$53K
- Michael JohnsonCharleston$23K
- Karen FernandezCharleston$22K
- Cole MillikenCharleston$17K
- Ettaleah BluesteinCharleston$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.